TRDN encodes triadin, a sarcoplasmic reticulum protein of the muscle calcium release complex that is expressed as multiple alternatively spliced isoforms (Trisk 51, Trisk 95, Trisk 32) from a single gene (PMID:12659871). Within skeletal muscle, Trisk 95 is the functionally decisive isoform for excitation-contraction coupling: its overexpression specifically abolishes depolarization-induced calcium release without altering caffeine-induced release or dihydropyridine receptor activation, identifying it as a direct regulator of the calcium release step (PMID:16176928). This regulation is mediated by three lysine residues (K218, K220, K224) in the luminal domain of Trisk 95, which are jointly required for binding and activating the RyR1 channel; the same residues mediate calsequestrin binding, so a single triadin monomer cannot simultaneously engage RyR1 and calsequestrin (PMID:27595738). A distinct isoform, Trisk 32, instead associates with IP3 receptors and potentiates IP3-mediated calcium release independently of ryanodine receptors (PMID:21811790). In the heart, loss-of-function and missense TRDN mutations impair RyR2-mediated calcium release: a homozygous p.L56P substitution alters cardiac TRISK32 dynamics and reduces caffeine-induced calcium release when co-expressed with RyR2 (PMID:31437535), and a deep intronic variant disrupts cardiac triadin splicing to abolish triadin protein in patient-derived iPSC cardiomyocytes (PMID:32402482), establishing TRDN as a cause of recessive arrhythmia (triadin knockout syndrome). Triadin also functions outside striated muscle, where Trisk 95 is transcriptionally induced by glucose and is required for glucose-evoked calcium flux and mitochondrial fragmentation in skin cells (PMID:32699238).